Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
29. October 2012
With the announcement today of the strategic partnership with and acquisition of a share in Beta Renewables (Company announcement No. 68), the aforementioned share buyback program is hereby terminated.
25. October 2012
Sales growth in DKK was 6% (2% LCY, 3% organic) compared with the first 9 months of 2011. EBIT grew by 12%, and the EBIT margin increased to 24.6%. The expectations for full-year 2012 EBIT growth, EBIT margin and net profit growth are maintained, as is the expectation for free cash flow.
1. April 2013
26. February 2013
| Copyright © 2010 Novozymes. All Rights Reserved.